Q1 Earnings Forecast for Sage Therapeutics Issued By Wedbush

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Investment analysts at Wedbush upped their Q1 2025 EPS estimates for Sage Therapeutics in a research report issued to clients and investors on Wednesday, April 16th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will earn ($1.17) per share for the quarter, up from their previous forecast of ($1.24). Wedbush currently has a “Neutral” rating and a $6.00 price objective on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($3.52) per share. Wedbush also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($4.15) EPS, FY2026 earnings at ($2.80) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.22) EPS and FY2029 earnings at ($0.90) EPS.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%.

Other research analysts have also issued reports about the stock. Bank of America assumed coverage on shares of Sage Therapeutics in a report on Tuesday, March 11th. They issued an “underperform” rating and a $5.00 target price on the stock. HC Wainwright reissued a “neutral” rating and set a $12.00 price objective (down previously from $14.00) on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Scotiabank lowered their target price on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating for the company in a research note on Wednesday, February 12th. Piper Sandler reduced their price target on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Finally, Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, February 12th. Three analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Sage Therapeutics has a consensus rating of “Hold” and an average price target of $8.81.

Sage Therapeutics Stock Up 0.8 %

Shares of NASDAQ:SAGE opened at $7.43 on Friday. The company has a market capitalization of $456.80 million, a P/E ratio of -1.13 and a beta of 0.48. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $14.97. The stock’s fifty day simple moving average is $7.47 and its 200-day simple moving average is $6.72.

Hedge Funds Weigh In On Sage Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Caligan Partners LP acquired a new stake in Sage Therapeutics in the 4th quarter valued at $16,575,000. State Street Corp boosted its position in shares of Sage Therapeutics by 18.2% in the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock worth $21,127,000 after buying an additional 451,377 shares during the period. Millennium Management LLC boosted its position in shares of Sage Therapeutics by 8.3% in the fourth quarter. Millennium Management LLC now owns 1,623,785 shares of the biopharmaceutical company’s stock worth $8,817,000 after buying an additional 124,720 shares during the period. Boothbay Fund Management LLC acquired a new stake in shares of Sage Therapeutics in the fourth quarter valued at about $7,540,000. Finally, Geode Capital Management LLC raised its holdings in shares of Sage Therapeutics by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 1,256,903 shares of the biopharmaceutical company’s stock valued at $6,827,000 after buying an additional 14,049 shares during the period. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.